25/07/2025
The world's first mRNA lung cancer vaccine has begun human testing in a groundbreaking international trial that could transform cancer treatment. BioNTech, the pharmaceutical company that co-developed a leading COVID-19 vaccine, is now testing BNT116 against non-small cell lung cancer, the most common and lethal form of the disease. The experimental vaccine works by teaching the immune system to identify and attack cancer cells, potentially offering new hope for patients facing advanced lung cancer diagnoses. Researchers are conducting the initial safety trial at 34 medical centers across seven countries, including major sites in the UK, US, and Germany. This represents the first time mRNA technology has been tested as a lung cancer treatment in humans.
